glp 1 hashimoto Association between autoimmune diseases and glucagon-like peptide-1 receptor agonists: A real-world evidence study Can a patient with Hashimoto's

Description

Using 23andMes unique crowdsourced approach to research, we were able to conduct the first large-scale genome-wide association study (GWAS) just seven months after starting the study, a very rapid rate for a study of this kind

See more at Good Morning America

Lilly Launches Trulicity in the US First Ever Ready-to-Use Once-Weekly GLP-1 Receptor Agonist Eli Lilly launches Trulicity in the US first ready-to-use once-weekly GLP-1, available with a savings program for commercially insured patients

Hence, the expanding role of GLP-1-based medicines, together with newer more powerful GLP-1-based medicines (Figure 1), holds great promise for achieving improved health for substantial populations of individuals living with the complications of chronic cardiometabolic disorders